Nenad Hrvatin

Mr. Nenad Hrvatin

Pediatrics, Clinical Hospital Centre Rijeka, Rijeka, Primorsko-Goranska Županija, Croatia
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Dragan PrimoracDragan Primorac
Dragan Primorac
Petar BrlekPetar Brlek
Petar Brlek
Luka BulićLuka Bulić
Luka Bulić
NHNenad Hrvatin
Nenad Hrvatin
VSVedrana Skaro
Vedrana Skaro
Ali MobasheriAli Mobasheri
Ali Mobasheri
Extracellular vesicles (EVs) have emerged as essential mediators of intercellular communication, transporting a complex repertoire of lipids, proteins, and nucleic acids that mirror the physiological and pathological status of their parent cells. This review provides a comprehensive overview of EVs from their biogenesis and molecular composition to their translational potential in human disease. This review outlines the major classes of EVs, including exosomes, microvesicles, apoptotic bodies, and oncosomes, together with recent developments in their isolation, molecular characterization, and omics-based profiling. Special focus is given to the role of EVs in viral infection, inflammation, and immune regulation, as well as their contribution to disease development and cancer biology. Moreover, we highlight the emerging clinical applications of mesenchymal stem cell-derived EVs (MSC-EVs) in regenerative medicine and oncology, alongside the therapeutic modulation of EV signaling by photobiomodulation (PBM). Finally, we address key translational challenges related to standardization, scalability, and regulatory validation. As exosome-based therapeutics fall under strict FDA and EMA oversight, their translation further depends on harmonized quality controls and robust safety evaluation. By integrating molecular mechanisms with clinical applications, this review emphasizes the transformative potential of EVs as next-generation diagnostic and therapeutic tools in precision medicine.

30 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Petar BrlekPetar Brlek
Petar Brlek
VSVedrana Skaro
Vedrana Skaro
NHNenad Hrvatin
Nenad Hrvatin
Luka BulićLuka Bulić
Luka Bulić
APAna Petrovic
Ana Petrovic
Dragan PrimoracDragan Primorac
Dragan Primorac
The rapid evolution of sequencing technologies has profoundly advanced precision oncology. Whole-exome sequencing (WES), whole-genome sequencing (WGS), and whole-transcriptome sequencing (RNA-Seq) enable comprehensive characterization of tumor biology by detecting actionable mutations, gene fusions, splice variants, copy number alterations, and pathway dysregulation. These approaches also provide critical insights into biomarkers such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI), which are increasingly essential for guiding therapeutic decisions. Importantly, comprehensive genomic profiling not only refines patient stratification for targeted therapies but also sheds light on tumor–immune interactions and the tumor microenvironment, paving the way for more effective immunotherapeutic combinations. WGS is considered the gold standard for detecting germline mutations and complex structural variants, while WES remains central for detecting somatic driver mutations that guide targeted therapies. RNA-Seq complements these methods by capturing gene expression dynamics, identifying clinically relevant fusions, and revealing mechanisms of resistance. Together with advances in bioinformatics and artificial intelligence, these tools translate molecular data into actionable strategies for patient care. This review integrates insights from WGS, WES, and RNA-Seq with an overview of FDA- and EMA-approved targeted therapies, organized by tumor type, and highlights the molecular signaling pathways that drive cancer development and treatment. By bridging genomic profiling with regulatory-approved therapies, we outline current advances and future perspectives in delivering personalized cancer care.

Verified
Journal Article
Open access
PDF file
Dragan PrimoracDragan Primorac
Dragan Primorac
Petar BrlekPetar Brlek
Petar Brlek
Luka BulićLuka Bulić
Luka Bulić
NHNenad Hrvatin
Nenad Hrvatin
VSVedrana Skaro
Vedrana Skaro
Ali MobasheriAli Mobasheri
Ali Mobasheri
Extracellular vesicles (EVs) are membrane-bound nanoparticles released by almost all cell types into the extracellular space, acting as important mediators of intercellular communication by transferring proteins, lipids, and nucleic acids horizontally. EVs are generally classified into small EVs (200 nm), microvesicles, and apoptotic bodies, with current classification methods focusing on physical properties, molecular composition, and cellular origin, as detailed in the MISEV2023 guidelines. EVs are highly promising for diagnostic and therapeutic applications due to their intrinsic biocompatibility, stability in biological fluids, capacity to carry diverse molecular cargo, and potential for drug delivery and functionalization to enable targeted delivery and tissue repair. This narrative review discusses the emerging roles of EVs across various medical fields, including obstetrics and gynecology, ophthalmology, otorhinolaryngology, urology, oncology, orthopedics, neurology, immunology, wound healing, chronic pain management, dermatology, and cardiology. In each discipline, EVs show potential as biomarkers for diagnosing physiological or pathological conditions and as carriers for targeted drug delivery and regenerative treatments. Exosomes, a major type of small EVs, have especially attracted attention as versatile nanocarriers for precision medicine. However, translation into clinical practice requires addressing key pitfalls, including the standardization of isolation and characterization protocols, dose definition, GMP-compliant large-scale production, and regulatory approval. Ongoing interdisciplinary collaboration across disciplines and thorough clinical testing will be essential to unlock the full biomedical potential of EVs and establish them as transformative tools in personalized healthcare.

4 January 2026 in AI
Verified
Journal Article
Open access
PDF file
Luka BulićLuka Bulić
Luka Bulić
Petar BrlekPetar Brlek
Petar Brlek
NHNenad Hrvatin
Nenad Hrvatin
EBEva Brenner
Eva Brenner
VSVedrana Skaro
Vedrana Skaro
Dragan PrimoracDragan Primorac
Dragan Primorac
Cancer remains one of the main global public health challenges, with rising incidence and mortality rates demanding more effective diagnostic and therapeutic approaches. Recent advances in artificial intelligence (AI) have positioned it as a transformative force in oncology, offering the ability to process vast and complex datasets that extend beyond human analytic capabilities. By integrating radiological, histopathological, genomic, and clinical data, AI enables more precise tumor characterization, including refined molecular classification, thereby improving risk stratification and facilitating individualized therapeutic decisions. In diagnostics, AI-driven image analysis platforms have demonstrated excellent performance, particularly in radiology and pathology. Prognostic algorithms are increasingly applied to predict survival, recurrence, and treatment response, while reinforcement learning models are being explored for dynamic radiotherapy and optimization of complex treatment regimens. Beyond direct patient care, AI is accelerating drug discovery and clinical trial design, reducing costs and timelines associated with translating novel therapies into clinical practice. Clinical decision support systems are gradually being integrated into practice, assisting physicians in managing the growing complexity of cancer care. Despite this progress, challenges such as data quality, interoperability, algorithmic bias, and the opacity of complex models limit widespread integration. Additionally, ethical and regulatory hurdles must be addressed to ensure that AI applications are safe, equitable, and clinically effective. Nevertheless, the trajectory of current research suggests that AI will play an increasingly important role in the evolution of precision oncology, complementing human expertise and improving patient outcomes.

23 May 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Petar BrlekPetar Brlek
Petar Brlek
BDBerina Divanović
Berina Divanović
Luka BulićLuka Bulić
Luka Bulić
KĐKlara Đambić
Klara Đambić
MMMarko Mesin
Marko Mesin
Dragan PrimoracDragan Primorac
Dragan Primorac
Introduction: Accurate detection and characterization of intracardiac masses remain a major challenge in cardiovascular imaging due to overlapping morphological features between tumors, thrombi, and vegetations, as well as the inherent limitations of echocardiography, including operator dependency and variable image quality. Although echocardiography is the first-line imaging modality for evaluating cardiac masses, diagnostic uncertainty frequently necessitates additional multimodality imaging. Artificial intelligence (AI), including machine learning and deep learning approaches, has emerged as a promising strategy to improve image interpretation, automate feature extraction, and enhance diagnostic consistency. Objective: This narrative review aims to examine current advances in AI-enhanced echocardiography for cardiac tumor detection, with a particular focus on detection, segmentation, classification, multimodal integration, and clinical translation. Methods: A narrative literature review was conducted using PubMed, Scopus, and Google Scholar databases. Relevant English-language studies published between 2016 and 2026 were identified using keywords including “artificial intelligence”, “machine learning”, “deep learning”, “echocardiography”, “cardiac tumors”, “intracardiac masses”, “multimodal imaging”, and “ultrasomics”. Original studies, reviews, and methodological papers related to AI-assisted cardiovascular imaging were evaluated. Discussion: Current evidence suggests that AI-driven techniques, including radiomics (ultrasomics), convolutional neural networks, and multimodal learning frameworks, can improve the detection, segmentation, and classification of intracardiac masses. Experimental studies have reported high diagnostic performance, with some deep learning models achieving diagnostic accuracies exceeding 95% under controlled conditions. AI-assisted systems may also reduce interobserver variability and improve workflow efficiency. Multimodal AI approaches integrating echocardiography with cardiac magnetic resonance imaging, computed tomography, electrocardiography, and clinical data appear particularly promising for improving diagnostic discrimination. However, current models remain limited by small and imbalanced datasets, insufficient external validation, data heterogeneity, and limited generalizability across institutions and imaging protocols. Additional barriers to clinical implementation include annotation variability, limited interpretability of deep learning models, and regulatory considerations. Conclusions: AI-enhanced echocardiography has substantial potential to improve the detection and characterization of intracardiac masses by augmenting diagnostic consistency and supporting clinical decision-making. Nevertheless, current evidence remains largely based on retrospective and experimental studies. Future progress will depend on large multicenter collaborations, standardized imaging datasets, explainable AI frameworks, and prospective clinical validation to enable safe and effective integration into routine cardiovascular practice.